Pathstone Holdings LLC Has $6.85 Million Stake in West Pharmaceutical Services, Inc. (NYSE:WST)

Pathstone Holdings LLC lowered its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 5.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,821 shares of the medical instruments supplier’s stock after selling 1,420 shares during the quarter. Pathstone Holdings LLC’s holdings in West Pharmaceutical Services were worth $6,850,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of WST. Northwest Investment Counselors LLC bought a new position in West Pharmaceutical Services in the third quarter valued at approximately $30,000. Crewe Advisors LLC boosted its stake in West Pharmaceutical Services by 322.7% in the 2nd quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 71 shares during the period. Quest Partners LLC increased its holdings in West Pharmaceutical Services by 5,633.3% during the 2nd quarter. Quest Partners LLC now owns 172 shares of the medical instruments supplier’s stock worth $57,000 after purchasing an additional 169 shares in the last quarter. Blue Trust Inc. raised its stake in shares of West Pharmaceutical Services by 332.1% in the 2nd quarter. Blue Trust Inc. now owns 242 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 186 shares during the period. Finally, Eastern Bank bought a new stake in shares of West Pharmaceutical Services in the third quarter valued at about $82,000. Institutional investors own 93.90% of the company’s stock.

Insider Buying and Selling

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 703 shares of the company’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $310.40, for a total transaction of $218,211.20. Following the sale, the vice president now directly owns 1,253 shares of the company’s stock, valued at approximately $388,931.20. This represents a 35.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.53% of the stock is currently owned by corporate insiders.

West Pharmaceutical Services Stock Down 1.3 %

NYSE:WST opened at $316.59 on Friday. The company has a market cap of $22.93 billion, a PE ratio of 46.97, a PEG ratio of 22.97 and a beta of 1.00. The stock has a 50-day simple moving average of $307.01 and a 200 day simple moving average of $314.66. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.23 and a current ratio of 3.00. West Pharmaceutical Services, Inc. has a 52-week low of $265.00 and a 52-week high of $413.70.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, October 24th. The medical instruments supplier reported $1.85 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.35. The business had revenue of $746.90 million for the quarter, compared to analyst estimates of $709.62 million. West Pharmaceutical Services had a net margin of 17.37% and a return on equity of 18.41%. The firm’s revenue for the quarter was down .1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.16 earnings per share. On average, sell-side analysts expect that West Pharmaceutical Services, Inc. will post 6.67 EPS for the current fiscal year.

West Pharmaceutical Services Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 20th. Investors of record on Wednesday, November 13th were given a $0.21 dividend. The ex-dividend date of this dividend was Wednesday, November 13th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.27%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.20. West Pharmaceutical Services’s payout ratio is currently 12.46%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.